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Abstract:  
 
Cardiovascular disease (CVD) is the number 1 cause of death in women, accounting for about 1 
in 3 deaths. This article reviews the 2011 American Heart Association effectiveness-based 
guidelines for CVD prevention in women. Risk assessment, prevention, and management of risks 
through lifestyle changes and pharmacotherapy are discussed. The article concludes with 
implications for nurse practitioners on ways to improve cardiovascular health among women in 
their practice. 
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Article: 
 
One in 3 women will die from cardiovascular disease (CVD), equating to approximately 1 death 
per minute among women.1 Moreover, coronary heart disease (CHD), about half of all of CVD, 
outranks breast cancer as a cause of death for women by 10-fold.1 Despite the fact that heart 
disease remains the leading cause of death for women, mortality rates have declined dramatically 
between 1980 and 2000.1 Nearly half (47%) of the decline is attributed to increased use of 
evidence-based therapies for secondary prevention of myocardial infarction (MI), treatment of 
heart failure, revascularization for CHD, and treatment for cardiovascular risk factors (eg, 
hypertension and dyslipidemia).1 Another 44% of the decline is attributed to a change in risk-
factor modification related to lifestyle and environmental changes (eg, decrease in cholesterol, 
systolic blood pressure [BP], smoking, and physical inactivity). Thus, nurse practitioners (NPs) 
have a major role in empowering women in their practice to engage in healthy-heart living and in 
providing evidence and effectiveness-based therapies to further improve outcomes. 
 
Using Clinical Guidelines in Practice 
 
The American Heart Association (AHA) periodically publishes clinical practice guidelines 
related to various cardiovascular conditions. As part of this process the AHA may collaborate 
with other organizations, including the American College of Cardiology, to systematically 
develop such guidelines based on strict criteria to support the recommendations provided. NPs 
may use information from guidelines, supplemented with clinical experience and patient 
preferences, to inform their treatment decisions—all of which make up an evidence-based 
practice. 
 
Many advances have been made since the first clinical guideline directed toward CVD 
prevention in women was published by the AHA in 1999.2 The 2011 Update to the AHA 
Guidelines for Prevention of CVD in Women highlights the evidence for control of major risk 
factors in women and encourages the application of preventive therapies.3 The 2011 guidelines 
have switched from using “evidence-based” to “effectiveness-based” therapies to encompass the 
benefits and risks observed in clinical practice.3 Other modifications made to the 2011 guidelines 
included defining a new concept of “ideal cardiovascular health” that is associated with a longer 
lifespan. In addition, several new factors that have been associated with an increased risk of 
CVD in women were identified. 
 
However, more research is needed to determine whether there is utility in screening for 
widespread use.3 The Class III interventions—those interventions that are deemed not useful, not 
effective, and potentially harmful—were unchanged from the prior 2007 guidelines. This was 
because of no new evidence related to these Class II interventions, also discussed below. 
 
Risk Assessment 
 
Risk assessment is the cornerstone of prevention in women. As part of the evaluation for CVD 
risk, NPs should obtain a comprehensive medical and cardiac history (including history of 
congenital heart disease, heart murmurs, rheumatic heart disease, hypertension, and CHD), 
family history (including premature CHD), and a pregnancy-complication history. NPs should 
also screen for depression. Although depression may not directly affect CVD outcomes, it is self-
reported by 26% of women surveyed4 and may affect CVD risk for lack of adherence to 
preventive interventions.3 
 
When obtaining the history, NPs should also determine if the woman has ongoing or past 
symptoms of CHD. NPs need to keep in mind that there are substantial differences between men 
and women in perceptions of pain and reporting of symptoms, as well as in type, frequency, and 
quality of symptoms. It is now recognized that shortness of breath is often the presenting 
symptom for CHD in women over age 65. 
 
Also, many women do not present with the “typical” complaint of chest pain or discomfort, arm 
or neck pain but will report overwhelming fatigue. The absence of chest pain at presentation is 
associated with an increase in mortality, especially among younger women.5 Furthermore, 
women who have chest pain and undergo coronary angiography often show no evidence of 
obstructive coronary disease. However, half of the women in the Women's Ischemic Syndrome 
Evaluation (WISE) study had microvascular disease, a disorder of blockages in the smallest 
vessels that are not seen in coronary angiography.6 
 
Physical exam should include measurement of BP, body mass index (BMI), and waist size. 
Laboratory tests should include a fasting lipid panel and a fasting glucose level. In addition, a 
Framingham risk assessment should be conducted if the woman does not have evidence of CVD 
or diabetes. Traditionally, the Framingham Risk Score was used to assess risk for CHD. 
However, a limitation of the score is that it focuses on 10-year risk, especially that of MI and 
death, while not considering family history. 
 
In 2007 the AHA guidelines used an algorithm simplifying risk stratification of women to reflect 
lifetime risk for CVD to incorporate stroke risk, rather than solely looking at CHD.7Stroke 
accounts for a higher proportion of CVD events than CHD for women compared to men, in part 
because women have unique risk factors for stroke (pregnancy, hormone therapy, and a greater 
prevalence of hypertension in older women).3 
 
Categories of Cardiovascular Risk 
 
According to the 2011 AHA guidelines, women should be classified into 1 of 3 categories; high 
risk, at risk, and ideal cardiovascular health. Goals for ideal cardiovascular health include total 
cholesterol (TC) less than 200 mg/dL (untreated), BP of 120/80 or less that is untreated, and 
fasting blood sugar of less than 100 mg/dL (untreated).3 Other goals include abstinence from 
smoking, lean BMI of < 25 kg/m2, physical activity as recommended for the person's age, and a 
healthy diet (such as the Dietary Approaches to Stop Hypertension [DASH] or a similar diet).3 If 
patients meet all of these guidelines, they are considered to be in the category of ideal 
cardiovascular health (Table 1). 
 
Table 1. Goals for Ideal Cardiovascular Health for Adults ≥ 20 years 
• Total cholesterol < 200 mg/dL (untreated) 
• BP < 120/80 mm Hg (untreated) 
• Fasting serum glucose < 100 mg/dL (untreated) 
• Body mass index < 25 kg/m2 
• Abstinence from smoking 
• Physical activity > 150 min/week at moderate intensity, > 75 min/week vigorous intensity, or a 
combination of the 2 (may be cumulative) 
• Heart-healthy diet (eg DASH-like diet) 
BP = blood pressure; DASH = Dietary Approaches to Stop Hypertension. 
Data from Mosca et al.3 
 
At-risk assessment is generated by examining specific risk factors. Major risk factors used to 
define at-risk women include cigarette smoking, hypertension, hypercholesterolemia, obesity, 
poor diet, physical inactivity, family history of premature CVD, and metabolic 
syndrome.3 Importantly, the 2011 guidelines added subclinical atherosclerosis, poor exercise 
capacity on a treadmill or abnormal heart rate recovery after stopping exercise, and systemic 
autoimmune collagen-vascular disease (eg, lupus or rheumatoid arthritis). 
 
A history of pregnancy complications was also added as a nontraditional risk factor, including 
gestational diabetes, pre-eclampsia, pregnancy-induced hypertension, preterm birth, or birth of 
an infant small for gestational age. These abnormalities appear in response to the vascular and 
metabolic stress of pregnancy and may be early indicators of cardiovascular risk. Although more 
research is needed in this area, a detailed pregnancy history may identify women who have a 
higher lifetime risk of CVD. 
 
The high-risk classification is characterized by symptomatic CHD, symptomatic cerebrovascular 
disease, symptomatic peripheral arterial disease, abdominal aortic aneurysm (with or without 
symptoms), end-stage or chronic kidney disease, diabetes mellitus, or a 10-year predicted CVD 
risk of ≥ 10%. In 2011, more women are classified as high risk because of a change in the cut-
point of a 10-year predicted risk for all CVD (not just CHD alone); the 2007 guidelines used ≥ 
20% 10-year predicted risk to define high risk.3 
 
Interventions to Prevent CVD 
 
The 2011 guidelines are divided into sections by various lifestyle and pharmacological 
interventions for women aimed toward primary and secondary prevention. Lifestyle approaches 
to prevention are the most cost effective and widely applicable strategy. Major risk-factor 
interventions and preventive drug interventions vary, in some cases, by risk status.3 
 
Lifestyle Interventions 
 
The following lifestyle interventions are adapted from Table 4 in the 2011 guidelines for the 
prevention of CVD in women.3 Additional evidence related to these interventions is included to 
provide NPs with more recent information to use in practice. 
 
Smoking Cessation Counseling 
 
Every woman should be advised by all health care providers not to smoke and to avoid 
environmental tobacco smoke.3 NPs should provide counseling at every patient visit by using the 
5 As (ask about smoking use, advise all tobacco users to quit, assess willingness to quit, assist 
with treatments/referral for treatment, and arrange for follow-up for ongoing support to maintain 
cessation efforts), developed by the US Department of Health and Human Services, to provide 
support for smoking cessation.8 However, a study that evaluated the effectiveness of the 5 As 
determined that persons who smoke tobacco need more than just advice; tobacco users were 
more likely to report quitting if they were offered cessation medications or behavioral 
counseling.9 The guidelines indicated that nicotine replacement and other medications (eg, 
buproprion and varenicline) should be used in conjunction with a behavioral program or formal 
smoking cessation program for women who would like to quit.3 This recommendation is 
supported by a Cochrane Review that determined that the combination of pharmacotherapy with 
behavioral support increases smoking cessation success compared to less intensive programs.10 
 
Physical Activity 
 
Women who need to lose weight or sustain weight loss should be advised to accumulate a 
minimum of 60 to 90 minutes of at least moderate-intensity physical activity (eg, brisk walking) 
on most, and preferably all, days of the week.3 All other women should be advised to engage in 
at least 150 minutes per week of moderate exercise, which translates to 30 minutes, 5 times a 
week, and may be accumulative (eg, 10 minutes of exercise 3 times a day).3 
 
Alternatively, they may participate in 75 minutes per week of vigorous exercise or an equivalent 
combination of moderate- and vigorous-intensity aerobic physical activity.3However, the aerobic 
activity should be performed in episodes of at least 10 minutes, preferably spread throughout the 
week.3 Additional cardiovascular benefits may be obtained by doubling the recommended 
amount of time exercising.3 Furthermore, women should be advised to engage in muscle-
strengthening activities that involve all major muscle groups at least 2 days per week.3 
 
Overall, it is important for NPs to get their patients up and moving. Some women have difficulty 
finding time for exercise. One technique is to tell women to walk in place while watching 
television (eg, during commercials) and hold a soup can in each hand, which will help in strength 
training. Another idea is to tell women to take the stairs any time they are available in lieu of 
using an elevator or park their vehicle farther away from their destination to promote walking on 
a daily basis. 
 
Cardiac Rehabilitation 
 
A comprehensive CVD risk-reduction regimen (eg, cardiovascular or stroke rehabilitation or a 
physician-guided home- or community-based exercise training program) should be 
recommended to women with a recent acute coronary syndrome (ACS) or coronary 
revascularization, new onset or chronic angina, recent cerebrovascular event, peripheral arterial 
disease, or current/prior symptoms of heart failure and a left ventricular ejection fraction (LVEF) 
of ≤ 35%.3 Research has shown that women are less likely to be referred for cardiac 
rehabilitation and are more likely to drop out of a program.11 Some women have competing 
social demands or are frequently responsible for caregiving of others; some believe they can 
return to their baseline activity without a formal program; some are uncomfortable participating 
in programs that have a predominantly male enrollment; and some do not want to participate 
because they may have little experience exercising before their cardiac diagnosis.11 
 
Furthermore, Medicare Part B and insurance companies reimburse only for certain cardiac 
diagnoses (eg, MI in the past 12 months, stable angina, status after revascularization, valve 
surgery, or heart/lung transplantation). For those individuals and conditions covered, co-pays and 
deductibles may be prohibitive, especially if patients are financially challenged. 
 
While NPs are unable to order cardiac rehabilitation based on current regulations, they have a 
responsibility to advocate for referrals and encourage eligible patients to attend. Strategies to 
facilitate referral and increased participation include automatically referring all eligible patients 
at the time of hospital discharge, providing patients with a choice of where they can attend, 
providing written invitations and culturally and age-appropriate program brochures, arranging 
for transportation or parking assistance if needed to attend, following up with those who are 
referred yet have not attended, and openly discussing potential barriers to not enrolling into 
cardiac rehabilitation and secondary prevention programs, despite being referred.11 
 
 
Dietary Intake and Weight Maintenance/Reduction 
 
Women should maintain or lose weight through an appropriate balance of physical activity, 
caloric intake, and formal behavioral programs when indicated, to maintain or achieve an 
appropriate body weight (eg, BMI < 25 kg/m2 in US women), waist size (eg, < 35 in), or other 
target metric of obesity.3 Women should be advised to consume a diet rich in fruits and 
vegetables; choose whole-grain, high-fiber foods; consume fish, especially oily fish, at least 
twice a week; and limit intake of saturated fat, cholesterol, alcohol, sodium, and sugar. 
 
Women also should be encouraged to avoid trans-fatty acids and artificial trans-fats. The latter 
occur when hydrogen is added to a vegetable oil to make it form a solid (like shortening or 
margarine), which is intended to increase the food's shelf life, taste, and texture. However, 
ingestion of trans-fat increases low-density lipoprotein cholesterol (LDL-C). Foods that are 
likely to contain trans-fat include processed, fried, and packaged foods. However, some brands 
avoid using trans-fat, so it is important for NPs to teach women to read food labels. To read more 
about trans-fatty acids, refer to http://www.cdc.gov/nutrition/everyone/basics/fat/transfat.html. 
 
Women should also be provided with education on obtaining a dietary plan customized to their 
weight and physical activity. Refer to www.choosemyplate.gov for more information about how 
to increase consumption of healthy foods and encourage weight reduction. 
 
NPs are encouraged to assist patients in weight reduction through a variety of support options 
(eg, in-person support and remote options such as the Internet or smartphone applications). For 
example, health behavior coaches combined with remote support have been used to obtain and 
maintain substantial weight loss in adults who were obese and had 1 or more cardiovascular risk 
factors.12 Motivational interviewing was the primary approach used in the intervention, and the 
level of behavior change was noteworthy.12 
 
Omega-3 Fatty Acids 
 
Women with hypercholesterolemia or hypertriglyceridemia should consume omega-3 fatty acids 
in the form of fish or in capsule form.3 However, there are widely variable amounts of 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in fish or in the supplements. 
Research has shown that protection against CHD is inversely related to tissue levels of EPA and 
more so with DHA levels.13 The recommended dose of EPA, per the guidelines, is 1800 
mg/day.3 NPs can educate their patients that 2 oily fish meals per week contain an equivalent of 
approximately 500 mg/day of combined EPA and DHA.13Furthermore, the following fish 
contain high levels of oil: herring, mackerel, salmon, albacore tuna, or trout.13 However, 
pregnant women should be counseled against eating fish with the potential for the highest level 
of mercury contamination (eg,, shark, swordfish, king mackerel, or tile fish).3 
 
Interventions to Control Major Risk Factors 
 
The following interventions to control major risk factors are adapted from Table 4 in the 2011 
guidelines for the prevention of CVD in women.3 Additional evidence is included to provide NPs 
with more recent information to be used in practice. 
 
BP 
 
An optimal BP of < 120/80 mm Hg should be encouraged through lifestyle approaches, such as 
weight control, increased physical activity, alcohol moderation, sodium restriction, and increased 
consumption of fruits, vegetables, and low-fat dairy products. Pharmacotherapy is indicated 
when BP is ≥ 140/90 mm Hg (≥ 130/80 mm Hg with chronic kidney disease or diabetes 
mellitus). Thiazide diuretics should be part of the drug regimen for most patients unless 
contraindicated or unless there are compelling indications for other agents in specific vascular 
diseases. Initial treatment of high-risk women with ACS or MI should be with beta-blockers or 
angiotensin-converting enzyme (ACE) inhibitors (or angiotensin receptor blockers [ARBs], if 
allergic) with the addition of other medications (such as thiazide diuretics) as needed to achieve 
targeted BP. However, ACE inhibitors are contraindicated in pregnancy and should be used with 
caution in women who may become pregnant. 
 
Lipid and Lipoprotein Levels 
 
The following lipid levels for women should be encouraged through lifestyle approaches: LDL-C 
< 100 mg/dL, HDL-C > 50 mg/dL, triglycerides < 150 mg/dL, and non–HDL-C (total cholesterol 
minus HDL) < 130 mg/dL. All women who have lipid levels above these values should continue 
lifestyle modifications and start LDL-lowering therapy based on goals for their level of risk. For 
example, women who are considered high-risk should combine lifestyle modifications with 
medication (eg, statins) to achieve an LDL-C < 100 mg/dL. Furthermore, a reduction to < 70 
mg/dL is reasonable in very high risk women (eg, those with recent ACS or multiple poorly 
controlled cardiovascular risk factors) or those with established CHD, but this may require an 
LDL-lowering drug combination. 
 
Likewise women who have very high LDL-C levels (≥ 190 mg/dL), LDL lowering therapy 
should be started, regardless of the presence of other risk factors or CVD. Otherwise, therapy is 
based on the LDL-C level. The guidelines also provide recommendations for women with 
abnormal high-sensitivity C-reactive protein (hsCRP) levels (> 2 mg/dL), low HDL-C (< 50 
mg/dL), or elevated non-HDL-C levels (> 130 mg/dL) in high-risk women after their LDL-C 
goal is reached (Table 2). 
 
Table 2. Recommendations for Lipid Goals and Therapy Based on Risk Level 
Risk Level Recommended Therapy Goal for LDL-C 
High-risk women 
Women with other atherosclerotic 
CVD 
Women with diabetes 
Women with a 10-yr absolute risk 
> 20% 
Lifestyle therapy plus drug therapy 
to lower LDL-C; may require 
combination pharmacologic therapy 
to get to goal 
LDL-C < 100 mg/dL 
LDL-C < 70 mg/dL for very-
high risk women with CHD (eg, 
recent ACS, multiple poorly 
controlled CV risk factors) 
Other at-risk women with LDL-C 
≥ 160 mg/dL, multiple risk 
factors, and 10-yr absolute risk < 
10% 
Lifestyle therapy plus therapy to 
lower LDL-C 
LDL-C < 130 mg/dL 
Risk Level Recommended Therapy Goal for LDL-C 
Other at-risk women with LDL-C 
≥ 190 mg/dL regardless of 
presence or absence of other risk 
factors or CVD 
Other at-risk women with LDL-C 
≥ 130 mg/dL, multiple risk 
factors, and 10-yr absolute risk 
10%-20% 
Lifestyle therapy alone LDL-C < 130 mg/dL 
Women age < 60 with CHD risk > 
10% 
Lifestyle therapy; add stain therapy 
if hsCRP is > 2 mg/dL 
hsCRP < 2 mg/dL 
Women with low HDL-C (< 50 
mg/dL) 
Women with high non-HDL-C (> 
130 mg/dL) who are high risk 
after LDL-C goal is reached 
Niacin or fibrate therapy HDL-C >50 mg/dL 
Non-HDL-C < 130 mg/dL in 
very high-risk women with 
recent ACS or multiple poorly 
controlled CV risk factors 
ACS = acute coronary syndromes; CHD = coronary heart disease; CV = cardiovascular; CVD = 
cardiovascular disease; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity 
C-reactive protein; LDL-C = low-density lipoprotein cholesterol. 
Data from Mosca et al.3 
 
Diabetes Mellitus 
 
Lifestyle and pharmacotherapy can be useful in women with diabetes mellitus to achieve an 
HbA1C < 7% if this can be accomplished without significant hypoglycemia. Since the 2011 
guidelines were published, the American Diabetes Association guidelines from 2013 indicated 
that HbA1C goals should be more individualized.14 
 
Preventive Drug Interventions 
 
The following preventive drug interventions are adapted from Table 4 in the 2011 guidelines for 
the prevention of CVD in women.3 
 
Aspirin Therapy 
 
Aspirin therapy, if indicated, should be given in the form of enteric-coated pills to prevent gastric 
upset. For women with CHD, aspirin therapy (75-325 mg/d) should be used, unless 
contraindicated. Aspirin therapy is also reasonable for women with diabetes mellitus, unless 
contraindicated. If a high-risk woman is intolerant of aspirin, clopidogrel should be substituted. 
For women who are classified as “at-risk” or “healthy,” aspirin can be useful for those older than 
65 (81 mg daily or 100 mg every other day) if BP is controlled. The benefits for ischemic stroke 
and MI prevention are likely to outweigh the risk of gastrointestinal bleeding and hemorrhagic 
stroke. Lower doses of aspirin are recommended for these women to offset the risk of bleeding 
with higher doses. However, for women who are younger than 65, the evidence for primary 
prevention of CVD is less compelling. 
 
Medications for Atrial Fibrillation (AF) 
 
Aspirin 75-325 mg/day should also be used in women with chronic or paroxysmal AF who have 
a contraindication to warfarin or are at low risk of stroke (< 1%/year) or have a CHADS2 score 
of 0-1. For example, a patient with a CHADS2 score of 0-1 would, in addition to having AF, 
have 1 or fewer of the following risk factors for stroke: congestive heart 
failure, hypertension, age > 75, diabetes, or a history of stroke/TIA. For women with chronic or 
paroxysmal AF, warfarin should be used to maintain the international normalized ratio at 2.0 to 
3.0, unless they are at low risk for stroke (< 1%/year) or high risk of bleeding. 
 
Dabigatran is useful as an alternative to warfarin for the prevention of stroke and systemic 
thromboembolism in patients with paroxysmal to permanent AF and risk factors for stroke or 
systemic embolization who do not have a prosthetic heart valve or hemodynamically significant 
valve disease, severe renal failure (creatinine clearance < 15 mL/min), or advanced liver disease 
(impaired baseline clotting function). Note, however, that since the 2011 guidelines were 
published, 2 other anticoagulants, rivaroxaban and apixaban, have also been approved by the 
Food and Drug Administration as alternatives to warfarin. 
 
Beta-Blockers 
 
Beta-blockers should be used for up to 3 years in all women after MI or ACS with normal left 
ventricular function, unless contraindicated. Long-term beta-blocker therapy, however, should be 
used indefinitely for women with decreased left ventricular function, unless contraindicated. 
Long-term beta-blocker therapy (> 3 years) may be considered in other women with coronary or 
vascular disease and normal left ventricular function. 
 
Renin-Angiotension-Aldosterone System (RAAS) Blockers 
 
ACE inhibitors should be used (unless contraindicated) in women after MI and in those with 
clinical evidence of heart failure, LVEF ≤ 40%, or diabetes mellitus. If these women are 
intolerant of ACE inhibitors, ARBs should be used instead. However, both of these drug classes 
have contraindications and precautions and require ongoing monitoring for side effects. Use of 
aldosterone blockade (eg, spirololactone) after MI is indicated in women who do not have 
significant hypotension, kidney dysfunction, or hyperkalemia, who are already receiving 
therapeutic doses of an ACE inhibitor and beta-blocker and have an LVEF ≤ 40% with 
symptomatic heart failure. 
 
Interventions That Should Not Be Used 
 
The 2011 guidelines identified and retained class III recommendations (not useful/maybe 
harmful) for hormone therapy for menopause.3 Hormone replacement and selective estrogen-
receptor modulators for primary or secondary prevention of CVD should not be used. 
Furthermore, the routine use of aspirin for women younger than 65 for primary prevention of MI 
is potentially harmful, thus should not be used.3 Antioxidant supplements (specifically, vitamins 
E and C and beta carotene) and folic acid supplements (with or without B6 and B12) for the 
primary or secondary prevention of CVD have not been found to improve outcomes. There is an 
exception for women of childbearing years; folic acid 0.4 mg should be taken to prevent neural 
tube defects. 
 
Implications for NP Practice 
 
Considering Patient Diversity 
 
The 2011 guidelines provide a new section on considering diversity of patients with each 
encounter. According to the guideline, diversity is defined broadly as considering age, language, 
culture, literacy, disability, frailty, socioeconomic status, occupational status, religious 
affiliation, race, and ethnicity.3 One of the main causes of health disparities in outcomes is lack 
of understanding of health beliefs, cultural values and preferences, and patients' inability to 
communicate their needs in their own language.3 NPs should assess cultural and social 
differences in their patients to provide culturally competent care. 
 
Educating Women about Heart Disease 
 
Risk-factor modification is tightly linked to knowledge of heart disease and use of preventive 
actions by women who are at risk for CVD. In 2012 the AHA surveyed 2,432 women over 25 to 
assess their awareness of heart disease, knowledge of CVD symptoms, and their use and barriers 
to preventive behaviors.4 Data from this national survey were compared to findings from a 
survey done in 1997. As a result of widespread educational and awareness campaigns regarding 
heart disease in women over the 15-year period, awareness of CVD as the leading cause of death 
nearly doubled (56% versus 30%; P < 0.001) and awareness of atypical symptoms of CVD 
improved yet remained low (18% versus 10%; P < 0.0001).4 
 
As in the past, all racial/ethnic groups improved in their level of awareness. However, black and 
Hispanic women have lower rates of awareness compared to white women. Insight into 
awareness among black women may increase through outreach programs in places of worship at 
the local level.4 These programs encourage women to take preventive action because many black 
women believe that God or a higher power determines their health.4 
 
In addition, only 21% of the women surveyed reported that their physicians had ever discussed 
their risk for heart disease when discussing their health; reporting was lower among Hispanic and 
younger women. These findings are consistent with past studies that report health care providers 
continue to underestimate cardiovascular risk in women and underuse preventive therapies.4 NPs 
have an opportunity to improve cardiovascular health by targeting these subgroups for more 
intensive patient education related to awareness of heart disease and adopting a heart-healthy 
lifestyle. Each patient encounter should be viewed as an opportunity to assess patient's 
knowledge of CV risk and to provide education. 
 
Improving Adherence 
 
According to the 2012 AHA National Survey by Mosca and colleagues,4 women engaged in 
preventive behaviors to improve their health and feel better, not to live longer (with the 
exception of black women and women older than 65). Thirty-five percent of the women reported 
they had no barriers to engaging in preventive behaviors, reporting that they lived a heart-healthy 
lifestyle. However, in the remaining 65% of the women, the most frequent barriers included lack 
of money or insurance coverage (16%), lack of confidence in their ability to achieve behavior 
change (14%), and lack of time to care for themselves (13%). 
 
Lack of time to engage in heart-healthy behaviors was an issue for younger women. The 
youngest age group (25-34) cited not having enough time to take preventive action along with 
women ages 35-44 who reported family obligations as a barrier to living a heart-healthy lifestyle. 
Thus, taking the additional time to counsel women for risk factors and educating them on the 
importance of prioritizing their own health, in addition to the health of their families, is 
imperative. 
 
NPs should also develop strategies to educate women and reduce system barriers to adherence. 
Many improvements have occurred to make women aware of risk factors, treatment, and control. 
Programs such as Go Red for Women®, Million Hearts™, and the Heart Truth Professional 
Education Campaign® have made significant strides in improving cardiovascular health in 
women and reducing death and disability from CVD and stroke. 
 
NPs face many challenges: lack of time available for patient visits, comorbidities, and lack of 
training in behavioral modification and reimbursement issues.15 At-risk populations of women 
who are nonadherent include those with low literacy level or low socioeconomic status, 
depression, older age, hearing impairment, poor cognitive function, and lack of fluency in 
English.4,16 However, more research is needed to develop evidence and effectiveness-based 
methods to improve adherence in all of these women. 
 
Areas of Further Research 
 
Research related to the identification of nontraditional risk factors and novel risk markers is 
ongoing. However, this research is not currently recommended by the guidelines for use in risk 
stratification for women. New imaging technologies are also under investigation, although these 
variables remain topics for research. 
 
Conclusion 
 
Despite declining mortality rates from CVD and improvements in knowledge of heart disease, 
symptoms, and preventive behaviors compared to 15 years ago, challenges lie ahead. NPs should 
remain diligent in assessing and treating women who are at risk for CVD throughout their 
lifespan. Pregnancy complications and atypical symptoms should alert the NP to assess for risk 
of CVD. 
 
Lifestyle adaptation is the cornerstone for primary and secondary prevention of CVD. NPs 
should advocate for policy changes, such as referral of eligible women to cardiac rehabilitation 
and other formal secondary prevention programs and further research in risk stratification. 
Furthermore, NPs should use innovative educational strategies, such as those incorporating 
motivational interviewing, to empower patients to be increase adherence to living a heart-healthy 
lifestyle. Finally, NPs should strive to obtain BP and cholesterol levels within the targeted range 
through pharmacologic therapy and lifestyle measures to improve outcomes, especially for those 
at highest risk. 
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